Infectious Diseases
NanoViricides Advances MPox Treatment Amid WHO's Extended Health Emergency
NanoViricides, Inc. progresses with NV-387, a broad-spectrum antiviral drug, as the WHO extends the MPox global health emergency, highlighting the drug's potential to fill gaps in current treatments.
GeoVax Advances Mpox Vaccine Development Amid Global Outbreak Concerns
GeoVax Labs accelerates its GEO-MVA vaccine candidate development following EMA's streamlined approval pathway, addressing the urgent need for diversified Mpox vaccine supply as global outbreaks expand.
NanoViricides Advances MPox Treatment with Adaptive Clinical Trial Design
NanoViricides, Inc. nears finalization of an adaptive clinical trial protocol for NV-387, a potential first-in-class treatment for MPox, highlighting its significance amid limited effective therapies.
Dutch Startup Innovates with Rapid Field Test for Infectious Diseases
Spotlight Diagnostics' new test kit offers a portable solution for detecting infectious diseases like malaria and Chlamydia, addressing the urgent need for accessible diagnostics amid rising disease prevalence due to climate change.
Study Reveals Critical Link Between WASH Access and Cholera in Low- and Middle-Income Countries
A recent study underscores the significant impact of water, sanitation, and hygiene (WASH) access on cholera prevalence in low- and middle-income countries, highlighting the need for targeted interventions to meet UN Sustainable Development Goals.
Tonix Pharmaceuticals to Showcase TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
Tonix Pharmaceuticals will present preclinical data on its TNX-801 mpox vaccine candidate at the Vaccine Congress 2025, highlighting its potential to address public health threats.
GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases
GeoVax Labs accelerates its GEO-MVA vaccine development for Mpox and smallpox, responding to global health threats and regulatory advancements.
GeoVax Secures Patent for Innovative Malaria Vaccine Design
GeoVax Labs, Inc. has been granted a U.S. patent for a novel vaccine construct aimed at preventing malaria, marking a significant step forward in the fight against the disease and other infectious threats.
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu
NanoViricides, Inc. highlights NV-387, its broad-spectrum antiviral candidate, as a potential game-changer in combating emerging COVID-19 variants and Bird Flu strains, showcasing its superior performance in animal models and readiness for cGMP manufacturing.
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections
BiomX Inc. has reported successful Phase 2 clinical trial results for treating diabetic foot bone infections and cystic fibrosis with bacteriophage therapy, offering a potential solution to the growing antibiotic resistance crisis.
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
NanoViricides, Inc. has begun animal trials for its antiviral candidate NV-387, targeting measles amidst increasing global outbreaks and vaccine challenges, highlighting a critical step towards addressing a significant public health gap.
Soligenix Develops Novel Therapy to Address Antibiotic-Resistant Bacterial Infections
Soligenix's SGX943 represents a potential breakthrough in combating antibiotic-resistant bacteria, offering a novel broad-spectrum therapy that could help address a critical public health challenge.
NanoViricides Highlights Potential Antiviral Solution Amid Changing COVID Booster Recommendations
NanoViricides' President Dr. Anil Diwan comments on the FDA's updated COVID-19 booster policy, emphasizing the need for alternative antiviral treatments and positioning the company's NV-387 drug candidate as a potential solution for respiratory viral infections.
New Research Illuminates Potential Link Between Epstein-Barr Virus and Multiple Sclerosis
Scientific research is uncovering a complex relationship between Epstein-Barr virus exposure and Multiple Sclerosis, highlighting the potential for deeper understanding of disease mechanisms and future treatment strategies.
NanoViricides Advances Broad-Spectrum Antiviral Drug, Eyes Multiple Phase II Trials
NanoViricides is progressing its NV-387 drug candidate across multiple viral infections, with pending Phase II trials for MPox and emerging programs for measles and avian flu, highlighting significant potential in antiviral treatment development.
NanoViricides Advances Promising Antiviral Drug Against Measles and MPox
NanoViricides is developing NV-387, a potential breakthrough treatment for Measles and MPox amid rising global case counts and limited medical interventions. The drug represents a critical advancement in addressing urgent infectious disease challenges.
GeoVax Reveals Promising Dual-Action Vaccine with Potential COVID-19 and Mpox Protection
A novel vaccine candidate, GEO-CM04S1, demonstrates robust immunogenicity against both COVID-19 and Mpox in immunocompromised and healthy populations, offering potential breakthrough in infectious disease prevention.
Rapid Diagnostic Test Developed for Bacterial Meningitis
Researchers at Amsterdam University Medical Center have created a new diagnostic test that can quickly and accurately detect bacterial meningitis by measuring protein levels in cerebrospinal fluid, potentially improving patient outcomes through faster diagnosis.
NanoViricides Advances Measles Drug Development with Promising Broad-Spectrum Antiviral
NanoViricides is developing NV-387, a broad-spectrum antiviral drug candidate targeting measles amid declining vaccination rates. The drug shows potential for addressing infectious disease challenges with its unique therapeutic approach.
Tonix Pharmaceuticals Presents Promising Single-Dose Mpox Vaccine Candidate
Tonix Pharmaceuticals revealed preclinical data for TNX-801, a single-dose mpox vaccine that demonstrates durable protection in animals, including immunocompromised subjects. The vaccine could potentially address global health emergency challenges related to mpox outbreaks.
GeoVax Highlights Mpox Threat After North Carolina Wastewater Detection
Wastewater samples in North Carolina reveal the first state detection of Clade I Mpox, a more virulent strain with higher transmissibility. GeoVax responds by emphasizing the need for expanded vaccine preparedness and domestic manufacturing capabilities.
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data
Tonix Pharmaceuticals presented preclinical data on TNX-801, a single-dose mpox vaccine that demonstrates robust protection across animal models, potentially offering a significant breakthrough in combating global mpox outbreaks.
Soligenix Advances COVID-19 Vaccine Candidate CiVax Amid Ongoing Global Health Threat
Soligenix is developing CiVax, a heat-stable COVID-19 vaccine candidate, in response to persistent global health risks from the virus, with recent preclinical studies showing promising protection against multiple variants.
Fidget Spinner Transforms into Rapid Bacterial Detection Device
Researchers have developed a novel diagnostic tool using a fidget spinner with nanoplasmonic technology to detect bacterial species quickly and accurately. This innovative device could revolutionize point-of-care diagnostics, especially in resource-limited settings.